Sep 20, 2018
Apomorphine has a more than 20 year history as a therapeutic adjunct in the management of idiopathic Parkinson Disease. And yet, no randomized, placebo-controlled clinical trial to show for it.
As of July 2018, now there is. In this week's episode of BrainWaves, Dr. Siegler discusses the relevance, the strengths, and the weaknesses of the recently published TOLEDO trial.
Produced by James E. Siegler. Music by Ondrosik and Rod Hamilton. Sound effects by Mike Koenig, Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast.
1. Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H and Lees A. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2018;17:749-759.